Dr. Daniel Roy, MD
Claim this profileCentre Hospitalier de l'Université de Montréal
Studies Brain Aneurysm
Studies Aneurysm
8 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Daniel Roy, MD is currently running
Endovascular Repair Techniques
for Brain Aneurysm
Intracranial bifurcation aneurysms are commonly repaired with surgical and with endovascular techniques. Wide-necked bifurcation aneurysms (WNBA) are a difficult subset of aneurysms to successfully repair endovascularly, and a number of treatment adjuncts have been designed. One particularly promising innovation is the WEB (Woven EndoBridge), which permits placement of an intra-saccular flow diverting mesh across the aneurysm neck, but which does not require anti-platelet agent therapy. Currently, which treatment option leads to the best outcome for patients with WNBA remains unknown. There is a need to offer treatment with the WEB within the context of a randomized care trial, to patients currently presenting with aneurysms thought to be suitable for the WEB.
Recruiting1 award N/A5 criteria
Comprehensive Aneurysm Management
for Brain Aneurysms
The uncertainty regarding the management of Unruptured Intracranial Aneurysms (UIAs) has not progressed in the last 30 years. The fundamental ethical basis for this study is that physicians should only offer a risky preventive treatment when it has been shown to be beneficial. Before that, such treatment should be offered as an RCT. The CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation. The prinicpal questions to be addressed are : do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management? when patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management? The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: the 10 year combined neurological morbidity and mortality (mRS>2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment. This study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple RCTs whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. Patients will be followed for 10 years according to a standard of car follow-up schedule. The primary outcome is survival without neurological dependency (mRS<3) at 10 years. The secondary outcomes are: the incidence of SAH during follow-up and related morbidity and mortality; the morbidity and mortality related to endovascular or surgical treatment of the UIA at one year; overall mortality at 1, 5 and 10 years; overall morbidity (mRS>2) at 1, 5 and 10 years; length of hospitalization; discharge to location other than home
Recruiting1 award N/A1 criteria
More about Daniel Roy, MD
Clinical Trial Related13 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Daniel Roy, MD has experience with
- Endovascular Management
- Surgical Management
- Microsurgery
- Endovascular Interventions
- Neurosurgery
- Radiation Therapy
Breakdown of trials Daniel Roy, MD has run
Brain Aneurysm
Aneurysm
Cerebral Aneurysm
Brain Arteriovenous Malformation
Congenital Anomalies
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Roy, MD specialize in?
Daniel Roy, MD focuses on Brain Aneurysm and Aneurysm. In particular, much of their work with Brain Aneurysm has involved treating patients, or patients who are undergoing treatment.
Is Daniel Roy, MD currently recruiting for clinical trials?
Yes, Daniel Roy, MD is currently recruiting for 4 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Daniel Roy, MD has studied deeply?
Yes, Daniel Roy, MD has studied treatments such as Endovascular management, Surgical management, Microsurgery.
What is the best way to schedule an appointment with Daniel Roy, MD?
Apply for one of the trials that Daniel Roy, MD is conducting.
What is the office address of Daniel Roy, MD?
The office of Daniel Roy, MD is located at: Centre Hospitalier de l'Université de Montréal, Montreal, Quebec H2L 4M1 Canada. This is the address for their practice at the Centre Hospitalier de l'Université de Montréal.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.